📰 Progressive Multifocal News

Progressive Multifocal News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Progressive Multifocal. Real-time updates on events, politics, business and more.

FDA Okays First Biosimilar for Multiple Sclerosis

August 25, 2023

Sandozs natalizumab-sztn injection (Tyruko) is on par with Biogens Tysabri (natalizumab) for treatment of relapsing forms of MS, the FDA said in approving the first biosimilar to treat MS.

Paulr Lee Drug Administration Division Of Neurology Drug Evaluation Medscape Medical News Eastern European

Source: medscape.com

Cellevolve Bio Receives FDA Clearance of IND Application and Orphan Drug Designation for CE-VST01-JC for the Treatment of Progressive Multifocal Leukoencephalopathy (PML)

October 25, 2022

/PRNewswire/ -- Cellevolve Bio, Inc. ("the Company" or "Cellevolve"), a clinical stage development and commercialization platform company focused on cell...

Cellevolve Bio Derrell Porter Drug Administration Prnewswire Cellevolve Bio Inc Company Or Cellevolve Investigational New Drug

Source: prnewswire.com

Cellevolve Bio Submits Investigational New Drug (IND) Application for Global Phase 2, Placebo-controlled Study of CE-VST01-JC for the Treatment of Progressive Multifocal Leukoencephalopathy (PML)

September 20, 2022

/PRNewswire/ -- Cellevolve Bio, Inc. ("the Company" or "Cellevolve"), a development and commercialization platform company focused on cell therapies, today...

Rajiv Khanna Cellevolve Bio Irene Cortese Derrell Porter Berghofer Medical Research Institute Professor Rajiv Khanna National Institutes Of Health

Source: prnewswire.com

IPO Alert: Inhibikase Therapeutics (IKT)

December 23, 2020

IPO Alert: Inhibikase Therapeutics (IKT) BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Inhibikase Therapeutics is scheduled to make its debut on the Nasdaq Global Select Market today (December 23), under the ticker symbol IKT. Atlanta, Georgia-based Inhibikase Therapeutics is a clinical stage pharmaceutical company developing therapeutics kinase inhibitors for Parkinsons disease and related disorders. The company has offered to sell 1.8 million shares of its common stock at a price of $10 each. The unde...

Bruxelles Capitale Kostenloser Wertpapierhandel Paulson Investment Company Fordham Financial Management Inc Nasdaq Global Select Market Georgia Based Inhibikase Therapeutics

Source: finanznachrichten.de

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation